American Herbal Products Association (AHPA) > News > AHPA in the News

AHPA in the News

FDA and FTC highlight attention to intravenous therapies and social media in COVID-19 warning letters

Excerpt from the June 2020 AHPA Report

Since the first week of March, the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) have been issuing warning letters alleging that marketers promoted a wide variety of products with claims to prevent, treat, mitigate, diagnose or cure COVID-19. AHPA has analyzed 135 COVID-19 related warning letters issued by either FDA or FTC or by the agencies jointly between March 6, 2020, and May 11, 2020, and made available in each agency’s coronavirus information center as of May 15, 2020.

AHPA goes virtual for the remainder of 2020

All in-person events to be held online in 2020

Dear AHPA members and friends in the herbal community,

I am reaching out today to let you know that all AHPA activities normally held as in-person meetings will instead be produced as virtual events, webinars or teleconferences for the balance of 2020.

Request for proposals: Slippery elm sustainable wild harvest study

Request for proposals: Slippery elm sustainable wild harvest study

Deadline extended to July 10, 2020

The AHPA Foundation for Education and Research on Botanicals (AHPA ERB Foundation) is issuing a request for proposals to award grant funding to eligible applicants in order to enhance and promote knowledge and understanding of sustainable harvest of slippery elm (Ulmus rubra).  The grant supports research effects of varying rates of wild slippery elm bark harvest on tree population health and recovery across multiple harvest sites in order to inform sustainable harvest and management decisions for the species. The anticipated amount of funding available for a sustainable wild slippery elm bark harvest research project is up to $10,000 annually for up to 5 years.

May 2020 AHPA in the News


AHPA Hemp-CBD Status Report

Updated in April 2020 to cover recent FDA and USDA actions

To help the herbal products industry understand the evolving regulatory landscape for hemp and hemp-derived cannabidiol (CBD) products, AHPA has updated its free Hemp-CBD Status Report to include recent actions taken by the Food and Drug Administration (FDA) and the U.S. Department of Agriculture (USDA).

April 2020 AHPA in the News


AOAC Scientists Approve Official Method of Analysis for Cannabinoids in Hemp

April 27, 2020: AHPA Chief Science Officer Dr. Holly Johnson chairs CASP working group involved creating requirements for testing standard

The new validation and approval will allow laboratories to evaluate hemp for tetrahydrocannabinol (THC) on a dry-weight basis, as described by the U.S. Department of Agriculture’s Interim Final Rule governing the production of hemp under the 2018 Agriculture Improvement Act, known as the Farm Bill.

Free webinar: Supplement cGMP Basics for Hemp-CBD Companies

Presented Dec. 10, 2019 -- Duration: 2 hours

This webinar provides an overview of dietary supplement current good manufacturing (cGMP) requirements for hemp-CBD products. Legal and industry experts provide strategies and resources to comply and document compliance with  federal manufacturing requirements designed to ensure supplement product quality and safety.

Free webinar: Preparing for FDA cGMP Facility Inspections

Presented December 17, 2019

This webinar is designed to help businesses in the dietary supplement industry understand the elements of current Good Manufacturing Practice (cGMP) regulations (21 CFR 111) that have been the primary focus of FDA inspections. This knowledge will assist businesses in better allocating and directing their compliance resources.

Oregon adopts temporary rule prohibiting unsubstantiated claims that goods prevent, treat, diagnose, or mitigate COVID-19 related conditions

April 17, 2020: AHPA has been working with other trade organizations to seek withdrawal of a much-broader proposed rule that the OR DOJ published for comment late last year and in amended form in March 2020.

The Oregon Department of Justice (OR DOJ) has temporarily adopted a rule declaring it “unfair and deceptive” (and thus unlawful) to represent that any product “will prevent, treat, diagnose, mitigate, or cure coronavirus, COVID-19 or a related condition, without first having competent and reliable scientific evidence upon which to base a reasonable belief in the truth of the representation.” The temporary rule is effective for six months, until October 14, 2020.
RSS
12345678910 Last

2021 Annual Fund Sponsors

    

AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.